Allergan's second-quarter revenues were down by 0.8 percent to $4,090 million, but increased by 1.2 percent on a currency-neutral basis. The operating loss widened to $1,263 million from $467.0 million a year earlier due to impairment charges. On an adjusted basis, the group posted operating income of $1,850 million, down ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.